OakChart

Agios Pharmaceuticals Inc

AGIOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:37 PM ET

32.41+0.65 (2.05%)
2026-11-11 18:37 CET
Market cap
1,899.56 USD m
Revenue, TTM
140.84 USD m
Net income, TTM
-372.90 USD m
Free cash flow, TTM
-335.97 USD m
EPS diluted, TTM
-6.32
P/E
-
Compare

Price

AGIO against its 20, 50 and 200-day averages
2050200beat
30.0035.0040.0045.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AGIOclose 32.4120-day 33.6550-day 33.16200-day 31.8132.41

29.5% under the 52-week high of 46.00 on 18 Nov 2025. 52-week low 22.24 on 19 Nov 2025. Last 15 sessions, 40.4% high to low

Profile

AGIO
52-week range, 43% of the way up
22.2446.00

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

IndexRUT
Employees540
IPOJul 24, 2013
Beta0.61
ATR, 14d1.90
Rel volume0.33
Short float11.18%
Insider own2.42%
Inst own116.62%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.94B
Enterprise Value1.34B
Income-372.90M
Sales140.84M
Book/sh16.38
Cash/sh10.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees540
IPOJul 24, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S13.76
P/B1.98
P/C3.08
P/FCF-
EV/EBITDA-
EV/Sales9.48
Quick Ratio9.21
Current Ratio9.69
Debt/Eq0.03
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.32
EPS next Y-3.22
EPS next Q-1.09
EPS this Y21.94%
EPS next Y41.98%
EPS next 5Y41.14%
EPS past 3/5Y-18.95% -8.46%
Sales past 3/5Y55.97% -
EPS Y/Y TTM9.13%
Sales Y/Y TTM214.44%
EPS Q/Q38.77%
Sales Q/Q330.01%
EarningsNov 05 BMO
EPS/Sales Surpr.12.41% 7.24%

Ownership

Insider Own2.42%
Insider Trans-2.94%
Inst Own116.62%
Inst Trans6.04%
ROA-30.44%
ROE-32.95%
ROIC-37.81%
Gross Margin89.95%
Oper. Margin-297.72%
Profit Margin-264.76%
SMA20-3.69%
SMA50-2.25%
SMA2001.90%
Trades-

Technical

Shs Outstand59.78M
Shs Float58.36M
Short Float11.18%
Short Ratio5.87
Short Interest6.52M
52W High46.00 -29.54%
52W Low22.24 45.74%
Volatility7.24% 5.70%
ATR (14)1.90
RSI (14)48.74
Beta0.61
Rel Volume0.33
Avg Volume1.11M
Volume186,698

Performance

Perf Week3.29%
Perf Month7.29%
Perf Quarter-3.16%
Perf Half Y12.66%
Perf YTD19.07%
Perf Year-26.10%
Perf 3Y53.32%
Perf 5Y-24.27%
Perf 10Y-49.53%
Recom1.60
Target Price45.38
Prev Close31.76
Price32.41
Change %2.05%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 29, 2026ResumedHH.C. WainwrightBuy$55+69.7%
Apr 20, 2026ReiteratedHH.C. WainwrightBuy$65 → $50+54.3%
Nov 24, 2025InitiatedTTruistBuy
Nov 20, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$34+4.9%
Nov 19, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$28-13.6%
Feb 24, 2025InitiatedHH.C. WainwrightBuy$58+78.9%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Oct 10, 2024ResumedRRaymond JamesOutperform$51+57.3%
Sep 27, 2024DowngradeLLeerink PartnersOutperform → Market Perform$60 → $56+72.8%
Feb 08, 2024InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
IRONDisc Medicine Inc3.92B
BEAMBeam Therapeutics Inc2.64B
FULCFulcrum Therapeutics Inc285.36M
CRSPCRISPR Therapeutics AG4.42B
VRTXVertex Pharmaceuticals Inc136.97B
BMYBristol-Myers Squibb Co126.56B
KROSKeros Therapeutics Inc189.58M
NVONovo Nordisk ADR136.21B
RIGLRigel Pharmaceuticals831.62M
PFEPfizer Inc166.38B

Insider trading

latest 14 of 81
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gheuens SarahChief Medical OfficerOct 26 '26Option Exercise25.017,866196,72962,511Oct 28 04:02 PM
Gheuens SarahChief Medical OfficerOct 26 '26Sale37.697,866296,47054,645Oct 28 04:02 PM
SARAH GHEUENSOfficerOct 26 '26Proposed Sale37.697,866296,468Oct 26 04:11 PM
Gheuens SarahChief Medical OfficerOct 21 '26Option Exercise25.011,48937,24056,134Oct 23 04:05 PM
Gheuens SarahChief Medical OfficerOct 22 '26Option Exercise25.0150012,50555,145Oct 23 04:05 PM
Gheuens SarahChief Medical OfficerOct 21 '26Sale37.531,48955,88254,645Oct 23 04:05 PM
Gheuens SarahChief Medical OfficerOct 22 '26Sale37.5250018,76054,645Oct 23 04:05 PM
SARAH GHEUENSOfficerOct 22 '26Proposed Sale37.5250018,760Oct 22 04:48 PM
SARAH GHEUENSOfficerOct 21 '26Proposed Sale37.531,48955,881Oct 21 05:32 PM
Gheuens SarahChief Medical OfficerAug 04 '26Sale30.4830,000914,40054,645Aug 06 04:13 PM
SARAH GHEUENSOfficerAug 04 '26Proposed Sale30.4830,000914,283Aug 04 04:08 PM
Gheuens SarahChief Medical OfficerJul 01 '26Option Exercise0.008,375088,652Jul 02 04:03 PM
Gheuens SarahChief Medical OfficerJul 01 '26Sale37.564,007150,50384,645Jul 02 04:03 PM
Gheuens SarahOfficerJul 01 '26Proposed Sale37.564,007150,503Jul 01 04:08 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Agios Beats On Record Mitapivat Sales, But A Sickle Cell Delay And Slowing Script Adds Complicate The Story (Earnings Whispers) -9.91%
  • Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press)
  • Agios Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 (GlobeNewswire)
  • Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA (GlobeNewswire) -17.94%
  • Loading…
  • Agios Faces First Clean Test Of Akvesme Launch Days After Sickle Cell Decision (Earnings Whispers)
  • A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
  • FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings (Stocktwits) +11.43%
  • Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET (GlobeNewswire)
  • Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ... (GuruFocus.com) -6.46%
  • Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
  • Agios Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Agios scraps sickle cell drug programme on underwhelming Phase II data (Clinical Trials Arena) -6.74%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.090-1.244-1.09055.3951.6510
2026Q22026-07-30-1.690-1.655-1.69344.7526.4010
2026Q12026-04-29-1.690-1.803-1.68620.7513.3010
2025Q42026-02-12-1.860-1.954-1.85219.9712.0910
2025Q32025-10-30-1.780-1.897-1.77912.9010.678
2025Q22025-07-31-1.930-1.808-1.93412.509.528
2025Q12025-05-01-1.550-1.771-1.5548.709.688
2024Q42025-02-13-1.440-1.691-1.68910.709.379
2024Q32024-10-3116.22015.21616.2229.009.445
2024Q22024-08-01-1.690-1.602-1.6928.609.348
2024Q12024-05-02-1.450-1.648-1.4468.208.379
2023Q42024-02-15-1.710-1.648-1.7167.107.929
2023Q32023-11-02-1.640-1.703-1.6377.407.538
2023Q22023-08-03-1.510-1.561-1.5076.706.468
2023Q12023-05-04-1.470-1.701-1.4665.605.249
2022Q42023-02-230.680-1.3690.6644.314.549

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-6.860-6.982-6.859117.91116.13
2020FY-4.740-4.674-4.745203.2199.05
2021FY26.55025.514-6.3600.000.56
2022FY-4.230-6.290-4.23114.2413.91
2023FY-6.330-6.258-6.32726.8227.72
2024FY11.64011.44111.63836.5035.15
2025FY-7.120-7.062-7.12054.0346.12
2026FY--5.558--182.14
2027FY--3.225--337.31
2028FY--1.452--498.95
2029FY-0.276--652.76
2030FY-1.956--817.49

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0795262.8253.5167.00
2026Q4S2026-11-06105263.1253.5167.00
2026Q4S2026-11-05105263.1253.5167.00
2026Q4S2026-10-28100459.6152.9065.80
2026Q4S2026-10-20100359.6952.9065.80
2026Q4S2026-10-19100260.5953.5165.80
2026Q4S2026-10-14101260.5953.5165.80
2026Q4S2026-10-13102260.5953.5165.80
2026Q4S2026-10-09108260.5953.5165.80
2026Q4S2026-10-07109160.7753.5165.80
2026Q4S2026-08-201010063.1753.5186.00
2026Q4S2026-08-061010063.1753.5086.00
2026Q4S2026-08-051010063.1653.5086.00
2026Q4S2026-07-311010060.2728.0786.00

Estimate history

EPS, annual-6.75-6.026-6.859-4.745-6.36-4.231-6.32711.638-7.12-6.3205
Period201720182019202020212022202320242025TTM
EPS, quarterly16.222-1.689-1.554-1.934-1.779-1.852-1.686-1.693-1.089
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual43.01194.387117.9120014.2426.82336.49854.028140.84
Period201720182019202020212022202320242025TTM
Sales, quarterly8.96410.738.72612.45512.8819.96720.74644.74555.385
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual48.82658.21968.40169.29454.33455.0455.94557.15658.44959.781
Period201720182019202020212022202320242025MRQ
Shares, quarterly57.02257.15657.88758.03958.2858.44959.34159.60559.781
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue140.8454.0336.5026.8214.240.000.00117.9194.39
Cost of Goods Sold Incl. D&A14.1511.529.829.5020.2618.7818.7717.948.57
Gross Profit126.6942.5126.6817.32-6.02-18.78-18.7799.9885.82
Selling, General and Administrative Excl. Other546.01514.64452.42408.81383.02359.64317.14526.31448.30
Research and Development338.01334.36295.63288.90271.35247.73211.02402.81341.32
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-419.31-472.13-425.74-391.49-389.05-378.42-335.92-426.33-362.48
Interest Expense0.000.000.000.000.00-17.83-0.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-373.91-413.80717.97-352.09-231.80-356.51-329.31-411.47-346.03
Income Taxes-1.02-1.0244.240.000.000.000.000.000.00
Consolidated Net Income-372.90-412.78673.73-352.09-231.80-356.51-329.31-411.47-346.03
Net Income From Continuing Operations-372.90-412.78673.73-352.09-231.80-356.51-329.31-411.47-346.03
Net Income-372.90-412.78673.73-352.09-231.80-384.42-327.37-411.47-346.03
EPS (Recurring)-6.25-7.1211.64-6.33-4.23-6.36-4.74-6.86-6.03
EPS (Basic, Before Extraordinaries)-6.32-7.1211.86-6.33-4.23-6.36-4.74-6.86-6.03
EPS (Diluted)-6.32-7.1211.64-6.33-4.23-6.36-4.74-6.86-6.03
EBITDA-413.88-466.95-420.08-384.86-370.49-359.64-317.14-409.71-355.31
Non-Operating Income (Expense)45.4058.341,143.7139.40157.2521.916.6114.8616.45
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense51.2441.5233.8544.7749.3053.5161.6072.3773.36
Price To Earnings Ratio--2.89------
Price To Sales Ratio14.1029.2152.1246.21108.04-14.7124.3028.05
Gross Margin89.9578.6773.1064.57-42.30--84.7990.92
Operating Margin-297.72-873.87-1,166.47-1,459.52-2,732.07---361.57-384.03
Net Margin-264.76-764.011,845.92-1,312.63-1,627.82---348.97-366.61
Shares Outstanding59.7858.4557.1655.9555.0454.3369.2968.4058.22
Market Capitalization1,899.561,899.561,874.011,244.701,542.851,785.123,001.033,205.602,682.63

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue55.3844.7420.7519.9712.8812.468.7310.73
Cost of Goods Sold Incl. D&A3.984.352.683.153.052.962.362.63
Gross Profit51.4140.4018.0616.829.839.496.368.10
Selling, General and Administrative Excl. Other128.57150.95128.09138.40126.70136.55112.99133.14
Research and Development72.0399.4079.7886.7985.4290.6871.4781.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-77.16-110.55-110.03-121.58-116.87-127.06-106.63-125.04
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-65.05-100.70-99.11-109.06-103.43-112.02-89.29-105.40
Income Taxes0.000.000.00-1.020.000.000.00-8.88
Consolidated Net Income-65.05-100.70-99.11-108.04-103.43-112.02-89.29-96.52
Net Income From Continuing Operations-65.05-100.70-99.11-108.04-103.43-112.02-89.29-96.52
Net Income-65.05-100.70-99.11-108.04-103.43-112.02-89.29-96.52
EPS (Recurring)-1.09-1.69-1.69-1.85-1.78-1.93-1.55-1.69
EPS (Basic, Before Extraordinaries)-1.09-1.69-1.69-1.85-1.78-1.93-1.55-1.69
EPS (Diluted)-1.09-1.69-1.69-1.85-1.78-1.93-1.55-1.69
EBITDA-75.71-109.20-108.66-120.31-115.50-125.80-105.35-123.67
Non-Operating Income (Expense)12.129.8510.9112.5213.4415.0417.3419.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.6715.9415.543.0912.3814.6911.368.61
Price To Earnings Ratio----3.632.952.572.89
Price To Sales Ratio14.1022.4530.1129.3952.1047.1445.4651.46
Gross Margin92.8290.2987.0784.2576.3076.2372.9275.52
Operating Margin-139.32-247.07-530.34-608.89-907.37-1,020.12-1,221.97-1,165.30
Net Margin-117.44-225.06-477.74-541.09-803.05-899.40-1,023.25-899.56
Shares Outstanding59.7859.6059.3458.4558.2858.0457.8957.16
Market Capitalization1,899.562,206.991,982.171,587.302,332.191,926.261,678.781,874.01

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments854.42893.71776.93783.121,020.02572.93564.88585.30423.94
Short Term Receivables10.584.112.812.214.380.0015.3210.443.84
Inventories32.9227.6219.088.490.000.007.330.870.00
Other Current Assets44.1340.1635.0238.9539.8463.7524.1817.1717.49
Total Current Assets942.05965.60833.84832.771,064.23636.68611.70613.78445.26
Net Property, Plant & Equipment41.2354.5569.7988.12104.23116.07126.1124.3224.43
Total Investments and Advances310.01638.3229.43313.87266.3897.61152.93220.12143.81
Intangible Assets-----0.000.00--
Other Assets3.934.724.063.962.902.600.000.240.89
Total Assets1,297.221,663.20937.121,238.721,437.74852.95890.74858.46614.40
Short Term Debt Incl. Current Port. of LT Debt18.3916.7815.0113.6611.167.416.920.000.00
Accounts Payable18.3616.649.7818.6216.7017.7221.9017.8822.77
Income Tax Payable0.000.87-------
Other Current Liabilities45.4646.8643.1730.3531.9769.2664.0875.6272.17
Total Current Liabilities82.2181.1667.9562.6359.8394.3992.8993.5094.94
Long Term Debt21.8240.2156.9972.0085.9497.79106.750.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.090.881.163.280.00261.2750.5877.42143.95
Total Liabilities104.11122.24126.10137.90145.76453.45250.21170.92238.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,193.111,540.96811.021,100.811,291.97399.50640.53687.54375.50
Total Shareholders Equity1,193.111,540.96811.021,100.811,291.97399.50640.53687.54375.50
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,193.111,540.96811.021,100.811,291.97399.50640.53687.54375.50
Total Liabilities & Stockholders Equity1,297.221,663.20937.121,238.721,437.74852.95890.74858.46614.40
Book Value Per Share20.4126.9614.5020.0023.785.779.3611.817.69
Tangible Book Value Per Share20.4126.9614.5020.0023.785.779.3611.817.69
Full-Time Employees540488386393392562536482382
Price to Book Ratio1.941.151.401.471.387.525.103.906.18
Return on Assets-27.8951.82-32.36-17.32-31.13-37.77-47.05-46.99-51.02
Return on Equity-30.2057.29-36.83-19.37-42.15-63.33-61.97-65.10-85.73
Return on Invested Capital-33.9842.61-40.56-19.76-27.90-65.83-55.06-50.33-83.80
Quick Ratio11.0611.5611.9913.1617.796.746.516.554.69
Current Ratio11.4611.9012.2713.3017.796.746.596.564.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-372.90-412.78673.73-352.09-231.801,604.71-327.37-411.47-346.03
Depreciation5.435.185.656.6218.5618.7818.7716.627.17
Other Funds (Non Cash)94.9867.67-1,049.4568.46-79.80-1,993.9915.8770.2369.54
Funds from Operations-272.49-339.94-370.07-277.00-293.05-370.50-292.72-324.62-269.32
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-59.20-33.04-19.77-19.06-16.43-36.821.97-46.00-35.10
Income Taxes Payable0.00-0.870.87------
Cash from Operating Activities-331.68-372.98-389.84-296.06-309.48-407.32-290.76-370.62-304.42
Capital Expenditures-4.28-4.32-1.69-1.00-4.88-5.74-14.11-12.17-6.99
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.041.32132.750.000.000.00-
Purchase or Sale of Investments384.84391.50-724.05256.75115.39-548.4290.66103.61-266.84
Purchase of Investments-548.33-641.76-1,542.43-417.93-1,030.78-1,378.22-557.03-488.57-933.32
Sale Or Maturity of Investments933.171,033.26818.38674.681,146.17829.80647.68592.18666.48
Other Uses-25.00-10.000.00-17.500.000.00-0.800.000.00
Other Sources0.000.001,089.140.000.001,802.940.000.000.00
Cash from Investing Activities355.56377.18363.44239.57243.261,248.7875.7591.44-273.82
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock11.978.6814.445.432.68-765.1911.32289.72546.02
Repurchase of Common Pref Stock0.000.000.000.000.00-802.490.000.000.00
Sale of Common Pref Stock11.978.6814.445.432.6837.3011.32289.72546.02
Proceedsfrom Stock Options0.000.000.000.000.000.000.00277.20515.82
Issuance or Reduction of Debt, Net0.000.000.000.00-0.33-0.58-0.34-0.110.00
Change in Long Term Debt0.000.000.000.00-0.33-0.58-0.34-0.110.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-0.33-0.58-0.34-0.110.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00250.540.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities11.978.6814.445.432.35-765.77261.52289.61546.02
Net Change in Cash35.8412.88-11.96-51.05-63.8775.6946.5110.43-32.22
Free Cash Flow-335.97-377.29-391.53-297.06-314.36-413.06-304.87-382.79-311.41
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments630.01617.58737.04854.42952.86938.94
Short Term Receivables32.9024.2216.1310.585.034.99
Inventories37.8430.1535.0932.9232.0330.85
Other Current Assets51.3545.7246.5944.1343.1944.69
Total Current Assets752.10717.67834.84942.051,033.111,019.46
Net Property, Plant & Equipment30.8533.8237.7641.2344.3347.36
Total Investments and Advances277.01347.25308.45310.01304.34400.47
Other Assets4.089.683.933.933.933.94
Total Assets1,064.041,108.421,184.991,297.221,385.701,471.24
Short Term Debt Incl. Current Port. of LT Debt19.6519.2318.8018.3917.9917.59
Accounts Payable19.9316.3413.7518.3619.5517.53
Income Tax Payable---0.000.000.00
Other Current Liabilities38.0134.6526.2945.4637.2235.29
Total Current Liabilities77.5970.2258.8482.2174.7670.41
Long Term Debt6.8811.9516.9421.8226.5331.17
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.240.240.090.090.090.10
Total Liabilities84.7082.4075.88104.11101.38101.68
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity979.341,026.021,109.121,193.111,284.331,369.56
Total Shareholders Equity979.341,026.021,109.121,193.111,284.331,369.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity979.341,026.021,109.121,193.111,284.331,369.56
Total Liabilities & Stockholders Equity1,064.041,108.421,184.991,297.221,385.701,471.24
Book Value Per Share16.3817.2118.6920.4122.0423.60
Tangible Book Value Per Share16.3817.2118.6920.4122.0423.60
Full-Time Employees---540--
Price to Book Ratio1.941.991.661.241.701.31
Return on Assets-30.44-31.89-30.84-27.89-25.2657.93
Return on Equity-32.95-34.34-32.82-30.20-27.5764.05
Return on Invested Capital-6.60-9.70-8.80-8.89-7.89-8.00
Quick Ratio9.219.7913.5911.0613.3914.04
Current Ratio9.6910.2214.1911.4613.8214.48

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-65.05-100.70-99.11-108.04-103.43-112.02
Depreciation1.451.351.361.271.371.26
Other Funds (Non Cash)19.1443.0717.6315.1514.1425.35
Funds from Operations-44.46-56.28-80.12-91.62-87.92-85.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-14.78-1.03-38.80-4.59-0.238.28
Income Taxes Payable0.000.000.000.000.00-0.68
Cash from Operating Activities-59.24-57.31-118.92-96.21-88.15-77.12
Capital Expenditures-1.18-1.21-0.77-1.12-1.55-0.88
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments85.1466.42142.0891.2097.1189.84
Purchase of Investments-87.50-151.57-148.18-161.08-174.98-130.80
Sale Or Maturity of Investments172.64217.99290.26252.27272.09220.64
Other Uses0.00-25.000.000.000.00-10.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities83.9640.21141.3190.0895.5678.97
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.183.152.082.564.430.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.183.152.082.564.430.07
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.183.152.082.564.430.07
Net Change in Cash28.90-13.9524.47-3.5811.841.91
Free Cash Flow-60.42-58.52-119.69-97.33-89.71-78.00

Revenue breakdown

Pharmaceutical Preparations2024: 36.50M 2025: 54.03M
Non-US2024: 103.00K 2025: 4.86M
United States2024: 36.40M 2025: 49.17M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.18%6.5M58.4M1.10M
2026-10-1511.84%6.9M58.3M1.10M
2026-09-3012.04%7.0M58.3M1.06M
2026-09-1512.97%7.6M58.3M1.10M
2026-08-3112.94%7.5M58.3M1.14M
2026-08-1413.10%7.6M58.3M1.13M
2026-07-3112.24%6.8M55.9M1.10M
2026-07-1511.91%6.6M55.7M1.15M
2026-06-3012.13%6.8M55.7M1.19M
2026-06-1512.39%6.9M55.7M1.10M
2026-05-2912.43%6.9M55.7M1.06M
2026-05-1513.37%7.5M55.7M1.05M
2026-04-3012.82%7.0M54.4M1.06M
2026-04-1513.21%7.1M53.6M924.20K
2026-03-3112.31%6.6M53.7M913.05K
2026-03-1311.53%6.2M53.7M1.08M
2026-02-2711.62%6.2M53.7M1.16M
2026-02-1311.79%6.3M53.7M1.68M
2026-01-3012.25%6.7M54.9M1.63M
2026-01-1513.57%7.4M54.9M1.56M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5017.5022.200.007.0050.000.000.976-0.0580.003
call15.0015.0019.200.005.5260.000.000.971-0.0570.003
call17.5012.5016.700.004.6440.000.000.965-0.0550.004
call20.0010.0014.200.003.8880.000.000.933-0.0870.007
call22.507.5011.508.473.0581.000.000.918-0.0820.008
call25.005.008.308.201.93710.000.000.896-0.0760.009
call30.000.203.204.900.8904550.000.783-0.0580.015
call35.000.000.500.200.7012,0000.000.281-0.0770.017
call40.000.000.150.100.9021,8590.000.077-0.0370.007
call45.000.000.050.031.0434090.000.026-0.0170.003
call50.000.000.450.801.30395.000.000.022-0.0190.003
call55.000.001.450.641.53942.000.000.019-0.0200.002
call60.000.001.450.351.75030.000.000.017-0.0210.002
call65.000.003.900.001.9300.000.000.016-0.0220.002
put12.500.002.450.003.5700.000.00-0.024-0.0570.003
put15.000.004.900.002.9300.000.00-0.029-0.0550.003
put17.500.000.200.052.27337.000.00-0.037-0.0480.004
put20.000.001.000.452.32413.000.00-0.067-0.0840.007
put22.500.001.450.251.8654.000.00-0.082-0.0790.008
put25.000.002.550.101.4103920.00-0.124-0.0760.011
put30.000.150.400.450.6415650.00-0.217-0.0550.015
put35.001.805.504.301.92946.000.00-0.711-0.0750.017
put40.005.8010.0011.002.3976.000.00-0.923-0.0330.007
put45.0010.8015.009.102.9180.000.00-0.974-0.0130.003
put50.0016.6020.000.003.3560.000.00-0.978-0.0140.003
put55.0020.9025.000.003.7470.000.00-0.981-0.0140.002
put60.0025.8030.000.004.0720.000.00-0.983-0.0140.002
put65.0031.0035.000.004.3410.000.00-0.984-0.0140.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-26144Filing for proposed sale of securities under Rule 144.SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-22144Filing for proposed sale of securities under Rule 144.SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03SCHEDULE 13G/ASEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-02SCHEDULE 13GSEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000371.11K3
2026-090000
2026-0800914.40K1
2026-0700150.50K1
2026-060000
2026-050000
2026-04001.20M6
2026-03001.25M7
2026-020000
2026-010077.60K1
2025-1200824.38K5
2025-1100116.20K2

Institutional holders

Manager% owned
BlackRock, Inc.10.86%
FARALLON CAPITAL MANAGEMENT, L.L.C.9.95%
STATE STREET CORP5.94%
Lynx1 Capital Management LP5.73%
D. E. Shaw & Co., Inc.5.22%
VANGUARD PORTFOLIO MANAGEMENT LLC4.87%
VANGUARD CAPITAL MANAGEMENT LLC4.51%
ARMISTICE CAPITAL, LLC4.04%
Erste Asset Management GmbH3.62%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.3.55%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.37%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
Nomura Small Cap Core Fund2.84%
iShares Russell 2000 ETF2.59%
VANGUARD SMALL-CAP INDEX FUND2.29%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.33%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Fidelity Small Cap Index Fund1.09%
Strategic Advisers U.S. Total Stock Fund0.90%
iShares Russell 2000 Value ETF0.87%

OakChart. AGIO. Cached 15 minutes.